Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
24 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Sprint Bioscience AB - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Sprint Bioscience AB - Product Pipeline Review - 2014', provides an overview of the Sprint Bioscience AB's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Sprint Bioscience AB's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Sprint Bioscience AB including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Sprint Bioscience AB's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Sprint Bioscience AB's pipeline products Reasons to buy - Evaluate Sprint Bioscience AB's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Sprint Bioscience AB in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Sprint Bioscience AB's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Sprint Bioscience AB and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Sprint Bioscience AB - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Sprint Bioscience AB and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 3 List of Figures 3 Sprint Bioscience AB Snapshot 4 Sprint Bioscience AB Overview 4 Key Information 4 Key Facts 4 Sprint Bioscience AB - Research and Development Overview 5 Key Therapeutic Areas 5 Sprint Bioscience AB - Pipeline Review 7 Pipeline Products by Stage of Development 7 Pipeline Products - Monotherapy 8 Sprint Bioscience AB - Pipeline Products Glance 9 Sprint Bioscience AB - Early Stage Pipeline Products 9 Preclinical Products/Combination Treatment Modalities 9 Discovery Products/Combination Treatment Modalities 10 Sprint Bioscience AB - Drug Profiles 11 Small Molecule to Inhibit Choline Kinase for Cancer 11 Product Description 11 Mechanism of Action 11 R&D Progress 11 Small Molecule to Inhibit MTH1 for Cancer 12 Product Description 12 Mechanism of Action 12 R&D Progress 12 Small Molecule to Inhibit Vps34 for Triple Negative Breast Cancer 13 Product Description 13 Mechanism of Action 13 R&D Progress 13 Small Molecule 1 for Cancer 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 Small Molecule to Inhibit PIP Kinase for Cancer 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 Small Molecules to Inhibit Tankyrases for Cancer 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 Sprint Bioscience AB - Pipeline Analysis 17 Sprint Bioscience AB - Pipeline Products by Target 17 Sprint Bioscience AB - Pipeline Products by Molecule Type 18 Sprint Bioscience AB - Pipeline Products by Mechanism of Action 19 Sprint Bioscience AB - Recent Pipeline Updates 20 Sprint Bioscience AB - Dormant Projects 21 Sprint Bioscience AB - Locations And Subsidiaries 22 Head Office 22 Appendix 23 Methodology 23 Coverage 23 Secondary Research 23 Primary Research 23 Expert Panel Validation 23 Contact Us 24 Disclaimer 24
List of Tables Sprint Bioscience AB, Key Information 4 Sprint Bioscience AB, Key Facts 4 Sprint Bioscience AB - Pipeline by Indication, 2014 6 Sprint Bioscience AB - Pipeline by Stage of Development, 2014 7 Sprint Bioscience AB - Monotherapy Products in Pipeline, 2014 8 Sprint Bioscience AB - Preclinical, 2014 9 Sprint Bioscience AB - Discovery, 2014 10 Sprint Bioscience AB - Pipeline by Target, 2014 17 Sprint Bioscience AB - Pipeline by Molecule Type, 2014 18 Sprint Bioscience AB - Pipeline Products by Mechanism of Action, 2014 19 Sprint Bioscience AB - Recent Pipeline Updates, 2014 20 Sprint Bioscience AB - Dormant Developmental Projects,2014 21
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.